EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting the Menin–KMT2A interaction in leukemia: Lessons learned and future directions

Florian Perner iD, Jayant Y Gadrey, Scott A Armstrong, Michael W M Kühn

International Journal of Cancer · 15.01.2026 · 158 (2) · 342-356

DOI: 10.1002/ijc.35332 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Cancer, online erschienen am 30.01.2025. Verfasst von Florian Perner und 3 weiteren Autor:innen. Beteiligte Einrichtung: Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School (MHH), Hannover, Germany. Hauptthemen laut MEDLINE: Myeloid-Lymphoid Leukemia Protein, Histone-Lysine N-Methyltransferase, Proto-Oncogene Proteins, Leukemia. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Emmy-Noether Programme of the German Research Foundation, NCI NIH HHS, DFG Research-Unit TARGET-MPN.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chromosomal rearrangements involving the Mixed Lineage Leukemia gene ( MLL1 , KMT2A ) are defining a genetically distinct subset in about 10% of human acute leukemias. Translocations involving the KMT2A ‐locus at chromosome 11q23 are resulting in the formation of a chimeric oncogene, where the N‐terminal part of KMT2A is fused to a variety of translocation partners. The most frequently found fusion partners of KMT2A in acute leukemia are the C‐terminal parts of AFF1, MLLT3, MLLT1 and MLLT10. Unfortunately, the presence of an KMT2A‐rearrangements is associated with adverse outcomes in leukemia patients. Moreover, non‐rearranged KMT2A‐complexes have been demonstrated to be crucial for disease development and maintenance in NPM1‐mutated and NUP98‐rearranged leukemia, expanding the spectrum of genetic disease subtypes that are dependent on KMT2A . Recent advances in the development of targeted therapy strategies to disrupt the function of KMT2A‐complexes in leukemia have led to the establishment of Menin–KMT2A interaction inhibitors that effectively eradicate leukemia in preclinical model systems and show favorable tolerability and significant efficacy in early‐phase clinical trials. Indeed, one Menin inhibitor, Revumenib, was recently approved for the treatment of patients with relapsed or refractory KMT2A‐rearranged acute leukemia. However, single agent therapy can lead to resistance. In this Review article we summarize our current understanding about the biology of pathogenic KMT2A‐complex function in cancer, specifically leukemia, and give a systematic overview of lessons learned from recent clinical and preclinical studies using Menin inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myeloid-Lymphoid Leukemia ProteinHistone-Lysine N-MethyltransferaseProto-Oncogene ProteinsLeukemiaHumansNucleophosminMolecular Targeted TherapyAnimalsOncogene Proteins, FusionTranslocation, GeneticAntineoplastic Agents

Stichwörter der Autor:innen

ALLAMLBleximenibKMT2AMLL1MeninNPM1NUP98RevumenibZiftomenibleukemiaresistance

Substanzen

Myeloid-Lymphoid Leukemia ProteinKMT2A protein, humanHistone-Lysine N-MethyltransferaseProto-Oncogene ProteinsMEN1 protein, humanNucleophosminNPM1 protein, humanOncogene Proteins, FusionAntineoplastic Agents

Autor:innen und Institutionen

  • Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School (MHH), Hannover, Germany.
  • DGHO, Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V. working group, Clinical and Translational Epigenetics, Berlin, Germany.
  • Department of Medicine, Tufts Medical Center, Boston, Massachusetts, USA.
  • Department of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Hematology and Medical Oncology, University Medical Center, Johannes Gutenberg-University, Mainz, Germany.

ORCID-Profile: Florian Perner

Förderung

  • Emmy-Noether Programme of the German Research Foundation
  • NCI NIH HHS
  • DFG Research-Unit TARGET-MPN
  • Deutsche Forschungsgemeinschaft (DFG)
  • Else Kröner-Fresenius-Stiftung
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Perner, F., Gadrey, J. Y., Armstrong, S. A., & Kühn, M. W. M. (2026). Targeting the Menin–KMT2A interaction in leukemia: Lessons learned and future directions. International Journal of Cancer, 158(2), 342-356. https://doi.org/10.1002/ijc.35332

Vancouver

Perner F, Gadrey JY, Armstrong SA, Kühn MWM. Targeting the Menin–KMT2A interaction in leukemia: Lessons learned and future directions. International Journal of Cancer. 2026;158(2):342-356. doi:10.1002/ijc.35332

BibTeX
@article{Perner2026,
  author = {Perner, Florian and Gadrey, Jayant Y and Armstrong, Scott A and Kühn, Michael W M},
  title = {Targeting the Menin–KMT2A interaction in leukemia: Lessons learned and future directions},
  journal = {International Journal of Cancer},
  year = {2026},
  volume = {158},
  number = {2},
  pages = {342--356},
  doi = {10.1002/ijc.35332}
}
Kostenlos starten →